1. Home
  2. EPSM vs MRKR Comparison

EPSM vs MRKR Comparison

Compare EPSM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsium Enterprise Limited Ordinary Shares

EPSM

Epsium Enterprise Limited Ordinary Shares

BUY

Current Price

$1.22

Market Cap

16.8M

Sector

N/A

ML Signal

BUY

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$0.89

Market Cap

19.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPSM
MRKR
Founded
2010
1999
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8M
19.5M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
EPSM
MRKR
Price
$1.22
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.87
AVG Volume (30 Days)
★ 711.6K
74.7K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.61
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$19.61
Revenue Next Year
N/A
$375.85
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.83
$0.84
52 Week High
$35.04
$2.46

Technical Indicators

Market Signals
Indicator
EPSM
MRKR
Relative Strength Index (RSI) 42.39 31.38
Support Level $1.04 N/A
Resistance Level $1.57 $1.31
Average True Range (ATR) 0.11 0.07
MACD -0.01 -0.02
Stochastic Oscillator 32.27 1.23

Price Performance

Historical Comparison
EPSM
MRKR

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: